- Home
- NOMA vs DXR Comparison
NOMA vs DXR Comparison
Compare NOMA & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOMA | DXR |
|---|---|---|
| Founded | 2023 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 71.4M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | NOMA | DXR |
|---|---|---|
| Price | $3.99 | $9.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 18.4K | 12.4K |
| Earning Date | 05-22-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.10 | $7.10 |
| 52 Week High | $10.00 | $14.76 |
Technical Indicators
Market Signals| Indicator | NOMA | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 37.48 |
| Support Level | $3.91 | $8.45 |
| Resistance Level | $5.13 | $9.88 |
| Average True Range (ATR) | 0.56 | 0.38 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 60.65 | 47.93 |
Price Performance
Historical ComparisonAbout NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through innovative technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.